ReviewCancers2020
Emerging Role of Circulating Tumor Cells in Gastric Cancer.
Review in Cancers, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 39 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
39 citing papers in PubMed, 1 synthesis or guideline pooled it, 58 citations in OpenAlex.
- Ivermectin, a potential anticancer drug derived from an antiparasitic drug.Pharmacological research · 2021Pooled it
- Liquid biopsy biomarkers for early detection of gastrointestinal cancers: Current landscape and emerging technologies.Clinical and translational medicine · 2026Review
- Nine-Year Recurrence-Free Survival in Gastric Signet-Ring Cell Carcinoma: A Case Report of Laparoscopic Radical Resection Combining Long-Term Systematic Therapy and Metformin Enteric-Coated Tablets.Case reports in medicine · 2026Article
- Salivary metabolic profile landscape for gastric cancer screening: a metabolomic approach.Cancer cell international · 2025Article
- Role of circulating tumor DNA methylation in gastric cancer initiation and progression: A comprehensive review.World journal of gastrointestinal oncology · 2025Review
- Melatonin for gastric cancer treatment: where do we stand?Naunyn-Schmiedeberg's archives of pharmacology · 2025Review
- A revolutionary era in advancing precision immuno-oncology; role of circulating tumor cells.The journal of liquid biopsy · 2024Review
- Design of buffer property for the new enrichment method of circulating tumor cell based on immunomagnetic-negative separation.Computational and structural biotechnology journal · 2024Article
- Integrin β5, a noninvasive diagnostic biomarker, is associated with unfavorable prognosis and immunotherapy efficacy in gastric cancer.BMC gastroenterology · 2024Article
- Circulating tumor cells: from new biological insights to clinical practice.Signal transduction and targeted therapy · 2024Review
- Exploring new frontiers: cell surface vimentin as an emerging marker for circulating tumor cells and a promising therapeutic target in advanced gastric Cancer.Journal of experimental & clinical cancer research : CR · 2024Article
- Extracellular vesicles-derived CXCL4 is a candidate serum tumor biomarker for colorectal cancer.iScience · 2024Article
- Article
- Liquid biopsy for gastric cancer: Techniques, applications, and future directions.World journal of gastroenterology · 2024Review
- A Novel Nomogram to Predict Resectable Gastric Cancer Based on Preoperative Circulating Tumor Cell.Clinical and translational gastroenterology · 2024Article
- Pharmacomicrobiomics in precision cancer therapy: bench to bedside.Frontiers in immunology · 2024Review
- Global progress and future prospects of early gastric cancer screening.Journal of Cancer · 2024Review
- Who are optimal candidates for primary tumor resection in patients with metastatic gastric adenocarcinoma? A population-based study.PloS one · 2024Article
- Article
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors at 7 institutions in 3 countries.
Funding
Abstract
With over 1 million incidence cases and more than 780,000 deaths in 2018, gastric cancer (GC) was ranked as the 5th most common cancer and the 3rd leading cause of cancer deaths worldwide. Though several biomarkers, including carcinoembryonic antigen (CEA), cancer antigen 19-9 (CA19-9), and cancer antigen 72-4 (CA72-4), have been identified, their diagnostic accuracies were modest. Circulating tumor cells (CTCs), cells derived from tumors and present in body fluids, have recently emerged as promising biomarkers, diagnostically and prognostically, of cancers, including GC. In this review, we present the landscape of CTCs from migration, to the presence in circulation, biologic properties, and morphologic heterogeneities. We evaluated clinical implications of CTCs in GC patients, including diagnosis, prognosis, and therapeutic management, as well as their application in immunotherapy. On the one hand, major challenges in using CTCs in GC were analyzed, from the differences of cut-off values of CTC positivity, to techniques used for sampling, storage conditions, and CTC molecular markers, as well as the unavailability of relevant enrichment and detection techniques. On the other hand, we discussed future perspectives of using CTCs in GC management and research, including the use of circulating tumor microembolies; of CTC checkpoint blockade in immunotherapy; and of organoid models. Despite the fact that there are remaining challenges in techniques, CTCs have potential as novel biomarkers and/or a non-invasive method for diagnostics, prognostics, and treatment monitoring of GC, particularly in the era of precision medicine.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.